{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:49:24Z","timestamp":1793710164075,"version":"4.6.1"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Medications targeting the calcitonin gene-related peptide (CGRP) pathway are exciting and novel therapeutic options in the treatment of migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>In this article, we have reviewed the role of these CGRP monoclonal antibodies in patients with episodic migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>We did an extensive literature search for all phase 2 and 3 studies involving CGRP monoclonal antibodies in episodic migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Erenumab, fremanezumab, galcanezumab, and eptinezumab have all undergone phase 3 trials and have been found to be effective for episodic and chronic migraine. They have the advantage of being targeted therapies for migraine with very favorable adverse effect profiles comparable to placebo. Importantly, they are effective in subgroups of patients who have failed previous preventive therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Increasing use of these medications will certainly revolutionize the treatment and outlook for patients with migraine all over the world.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0028-3886.315997","type":"journal-article","created":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T04:19:32Z","timestamp":1621138772000},"page":"S59-S66","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention"],"prefix":"10.4103","volume":"69","author":[{"given":"Karthik","family":"Nagaraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Vandenbussche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J","family":"Goadsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20240907","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: A disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol Rev"},{"key":"R3-8-20240907","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11916-011-0233-z","article-title":"Defining the differences between episodic migraine and chronic migraine","volume":"16","author":"Katsarava","year":"2012","journal-title":"Curr Pain Headache Rep"},{"key":"R4-8-20240907","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1468-2982.2008.01819.x","article-title":"The acute treatment of episodic and chronic migraine in the USA","volume":"29","author":"Bigal","year":"2009","journal-title":"Cephalalgia"},{"key":"R5-8-20240907","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1212\/WNL.0000000000001256","article-title":"Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine","volume":"84","author":"Lipton","year":"2015","journal-title":"Neurology"},{"key":"R6-8-20240907","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy","volume":"68","author":"Lipton","year":"2007","journal-title":"Neurology"},{"key":"R7-8-20240907","first-page":"22","article-title":"Systematic review of migraine prophylaxis adherence and persistence","volume":"20","author":"Hepp","year":"2014","journal-title":"J Manag Care Pharm"},{"key":"R8-8-20240907","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","article-title":"Calcitonin gene-related peptide: Physiology and pathophysiology","volume":"94","author":"Russell","year":"2014","journal-title":"Physiol Rev"},{"key":"R9-8-20240907","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bph.14075","article-title":"Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR Review 25","volume":"175","author":"Hay","year":"2018","journal-title":"Br J Pharmacol"},{"key":"R10-8-20240907","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.410280213","article-title":"Vasoactive peptide release in the extracerebral circulation of humans during migraine headache","volume":"28","author":"Goadsby","year":"1990","journal-title":"Ann Neurol"},{"key":"R11-8-20240907","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410330109","article-title":"The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats","volume":"33","author":"Goadsby","year":"1993","journal-title":"Ann Neurol"},{"key":"R12-8-20240907","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","article-title":"CGRP may play a causative role in migraine","volume":"22","author":"Lassen","year":"2002","journal-title":"Cephalalgia"},{"key":"R13-8-20240907","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/0333102410368444","article-title":"Calcitonin gene related peptide triggers migraine like attacks in patients with migraine with aura","volume":"30","author":"Hansen","year":"2010","journal-title":"Cephalalgia"},{"key":"R14-8-20240907","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies \u2013 successful translation from bench to clinic","volume":"14","author":"Edvinsson","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"R15-8-20240907","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.joca.2014.01.009","article-title":"Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain","volume":"22","author":"Benschop","year":"2014","journal-title":"Osteoarthritis Cartilage"},{"key":"R16-8-20240907","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1474-4422(15)00249-5","article-title":"Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: A multicentre, randomised, double-blind, placebo-controlled, phase 2b study","volume":"14","author":"Bigal","year":"2015","journal-title":"Lancet Neurol"},{"key":"R17-8-20240907","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: A randomized clinical trial","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"key":"R18-8-20240907","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","article-title":"Safety and efficacy of AMG 334 for prevention of episodic migraine: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"15","author":"Sun","year":"2016","journal-title":"Lancet Neurol"},{"key":"R19-8-20240907","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N Engl J Med"},{"key":"R20-8-20240907","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: A phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia"},{"key":"R21-8-20240907","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: A randomised, double-blind, placebo-controlled, phase 3b study","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet"},{"key":"R23-8-20240907","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.92.15_supplement.P1.10-002","article-title":"Assessment of the efficacy of erenumab during the open-label treatment (13\u201324 weeks) of subjects with episodic migraine who failed 2\u20134 prior preventive treatments: Results of the LIBERTY study","volume":"92","author":"Reuter","year":"2019","journal-title":"Neurology"},{"key":"R24-8-20240907","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1177\/0333102419835459","article-title":"Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study","volume":"39","author":"Goadsby","year":"2019","journal-title":"Cephalalgia"},{"key":"R25-8-20240907","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.92.15_supplement.P1.10-020","article-title":"Long-term efficacy of erenumab in patients with episodic migraine who have failed prior preventive migraine therapies","volume":"92","author":"Reuter","year":"2019","journal-title":"Neurology"},{"key":"R26-8-20240907","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): A randomised, double blind, placebo controlled, phase 3b trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"key":"R27-8-20240907","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N Engl J Med"},{"key":"R28-8-20240907","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1212\/WNL.92.15_supplement.S38.004","article-title":"Long-term efficacy and safety of fremanezumab in migraine: Results of a 1-year study","volume":"92","author":"Goadsby","year":"2019","journal-title":"Neurology"},{"key":"R30-8-20240907","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.92.15_supplement.P1.10-011","article-title":"Efficacy of fremanezumab in migraine patients who have failed at least one prior migraine preventive medication","volume":"92","author":"McAllister","year":"2019","journal-title":"Neurology"},{"key":"R31-8-20240907","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1212\/WNL.92.15_supplement.P2.10-001","article-title":"Impact of fremanezumab on response rates, acute medication use, and disability in patients with episodic migraine who have failed at least one prior migraine preventive medication","volume":"92","author":"Winner","year":"2019","journal-title":"Neurology"},{"key":"R32-8-20240907","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/0333102419885905","article-title":"Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine","volume":"40","author":"Brandes","year":"2020","journal-title":"Cephalalgia"},{"key":"R33-8-20240907","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1474-4422(14)70128-0","article-title":"Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: A phase 2, randomised, double-blind, placebo-controlled study","volume":"13","author":"Dodick","year":"2014","journal-title":"Lancet Neurol"},{"key":"R34-8-20240907","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaneurol.2017.3859","article-title":"Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: A randomized clinical trial","volume":"75","author":"Skljarevski","year":"2018","journal-title":"JAMA Neurol"},{"key":"R35-8-20240907","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial evaluation of galcanezumab for the prevention of episodic migraine evaluation of galcanezumab for the prevention of episodic migraine","volume":"75","author":"Staufer","year":"2018","journal-title":"JAMA Neurol"},{"key":"R36-8-20240907","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 phase 3 randomized controlled clinical trial","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"key":"R37-8-20240907","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/jnnp-2018-320242","article-title":"Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: A post-hoc analysis","volume":"90","author":"Goadsby","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R38-8-20240907","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1212\/WNL.90.15_supplement.S20.004","article-title":"Efficacy of galcanezumab in patients who failed to respond to preventives previously: Results from EVOLVE-1, EVOLVE-2 and REGAIN studies","volume":"90","author":"Zhang","year":"2018","journal-title":"Neurology"},{"key":"R39-8-20240907","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s10194-019-1024-x","article-title":"Galcanezumab in episodic migraine: Subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE \u2013 1 & EVOLVE \u2013 2)","volume":"20","author":"Silberstein","year":"2019","journal-title":"J Headache Pain"},{"key":"R40-8-20240907","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"key":"R41-8-20240907","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1212\/WNL.92.15_supplement.S17.004","article-title":"Eptinezumab demonstrates early relief from episodic and chronic migraine: Consistency of effect across 4 clinical trials","volume":"92","author":"Dodick","year":"2019","journal-title":"Neurology"},{"key":"R42-8-20240907","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40265-019-01069-1","article-title":"Erenumab for preventive treatment of migraine: A systematic review and meta-analysis of efficacy and safety","volume":"79","author":"Lattanzi","year":"2019","journal-title":"Drugs"},{"key":"R43-8-20240907","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1177\/0333102419829007","article-title":"Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine\u2014A meta-analysis of randomized controlled trials","volume":"39","author":"Xu","year":"2019","journal-title":"Cephalalgia"},{"key":"R44-8-20240907","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s10072-018-3547-3","article-title":"The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: A meta-analysis","volume":"39","author":"Zhu","year":"2018","journal-title":"Neurol Sci"},{"key":"R45-8-20240907","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/1756285610388343","article-title":"Possible sites of action of the new calcitonin gene-related peptide receptor antagonists","volume":"3","author":"Eftekhari","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"R46-8-20240907","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.tips.2016.06.002","article-title":"Wiping out CGRP: Potential cardiovascular risks","volume":"37","author":"MaassenVanDenBrink","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"R47-8-20240907","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1212\/WNL.92.15_supplement.S17.002","article-title":"Erenumab (AMG334) an antagonist to canonical CGRP-receptor does not impair vasodilatory or contractile responses to other agents in human isolated cerebral arteries","volume":"92","author":"Ohlsson","year":"2019","journal-title":"Neurology"},{"key":"R48-8-20240907","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.92.15_supplement.P1.10-010","article-title":"Evaluation of cardiovascular risks in adult patients with episodic or chronic migraine treated with galcanezumab: Data from three phase 3, randomized, double-blind, placebo-controlled studies","volume":"92","author":"Oakes","year":"2019","journal-title":"Neurology"},{"key":"R49-8-20240907","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1212\/WNL.92.15_supplement.S17.005","article-title":"Fremanezumab cardiovascular and cerebrovascular safety profile: Pooled data from placebo-controlled and long-term studies","volume":"92","author":"Ning","year":"2019","journal-title":"Neurology"},{"key":"R51-8-20240907","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.92.15_supplement.P1.10-017","article-title":"Immunogenicity assessment from phase 3 galcanezumab trials in patients with episodic or chronic migraine","volume":"92","author":"Martinez","year":"2019","journal-title":"Neurology"},{"key":"R52-8-20240907","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","article-title":"Erenumab in chronic migraine with medication overuse","volume":"92","author":"Tepper","year":"2019","journal-title":"Neurology"},{"key":"R53-8-20240907","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.92.15_supplement.P1.10-026","article-title":"The impact of fremanezumab on medication overuse in patients with chronic migraine","volume":"92","author":"Silberstein","year":"2019","journal-title":"Neurology"},{"key":"R54-8-20240907","first-page":"23","article-title":"Medication overuse in a post-hoc analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine","volume":"59","author":"Aurora","year":"2019","journal-title":"Headache"},{"key":"R55-8-20240907","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s10194-018-0923-6","article-title":"Early onset of efficacy with erenumab in patients with episodic and chronic migraine","volume":"19","author":"Schwedt","year":"2018","journal-title":"J Headache Pain"},{"key":"R56-8-20240907","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/head.13446","article-title":"The effect of beginning treatment with fremanezumab on headache and associated symptoms in the randomized phase 2 study of high frequency episodic migraine: Post-hoc analyses on the first 3 weeks of treatment","volume":"59","author":"Silberstein","year":"2019","journal-title":"Headache"}],"container-title":["Neurology India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.315997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:14:12Z","timestamp":1787843652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.315997"}},"subtitle":["Where Do We Stand Today?"],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":52,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/0028-3886.315997","relation":{},"ISSN":["0028-3886"],"issn-type":[{"value":"0028-3886","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}